Ardelyx, Inc. vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| ARDX | LLY | |
|---|---|---|
| Market Cap | $996.75 million | $1.06 trillion |
| Revenue (TTM) | $450.89 million | $79.67 billion |
| Net Income (TTM) | $-55,702,000 | $26.71 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| ARDX | LLY | |
|---|---|---|
| P/E Ratio | — | 41.35 |
| Price / Book | 6.69 | 31.20 |
| Price / Sales | 2.21 | 13.27 |
ARDX leads on 2 of 2 valuation factors.
Profitability
| ARDX | LLY | |
|---|---|---|
| Net Margin | -12.35% | 33.53% |
| Return on Equity | -37.38% | 78.84% |
LLY leads on 2 of 2 profitability factors.
Risk & Sentiment
| ARDX | LLY | |
|---|---|---|
| Short Interest | 0.76% | 1.29% |
ARDX leads on 1 of 1 risk & sentiment factors.
Dig deeper: ARDX overview, ARDX financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.